Verici Dx plc (VRCI) is a Medical diagnostics research company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Verici Dx plc in 2026. The next earnings report is expected on September 14, 2026.
Next earnings date
14 Sep 2026
In 26 days
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Verici Dx plc (VRCI) is scheduled to report earnings on September 14, 2026.
Verici Dx plc (VRCI) last reported earnings on September 30, 2025.
Verici Dx plc (VRCI) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.